[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610588":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":27,"collaborators":11,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":11,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":11,"enrollmentInfo":38,"targetDuration":11,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":11,"overallStatus":47,"whyStopped":11,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":11},{"fullName":5,"class":6},"Dong-A ST Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"DA-5218","EXPERIMENTAL",null,[13],"Drug: DA-5218",{"label":15,"type":16,"description":11,"interventionNames":17},"DA-5218-C","ACTIVE_COMPARATOR",[18],"Drug: DA-5218-C",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","DA-5218 + DA-5218-C placebo",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"DA-5218-C + DA-5218 placebo",[15],{"type":28,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100610588","phase-4-clinical-trial-to-evaluate-the-efficacy-and-safety-of-da-5218-in-patients-with-type-2-diabetes-100610588",false,"NCT07229534","Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes","A Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-5218 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin","Inclusion Criteria:\n\n* 7.0%≤HbA1c≤10.5% and fasting glucose≤270mg\u002FdL\n* Treated with 1,000mg\u002Fday dose of metformin for at least 8 weeks\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus\n* eGFR\\\u003C45mL\u002Fmin\u002F1.73m2\n* ALT and AST 3 times or higher than upper normal range\n* Determined by investigator as unfit to participate in a clinical trial due to other reasons","ALL","19 Years",{"count":39,"type":40},238,"ESTIMATED","INTERVENTIONAL",[43],"PHASE4","This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-5218 in patients with type 2 diabetes who have inadequate glycemic control with metformin",[46],"Diabete Mellitus","NOT_YET_RECRUITING","2025-11-13",{"date":50,"type":51},"2025-11-17","ACTUAL",{"date":53,"type":40},"2025-11",{"date":55,"type":40},"2027-11",{"name":5,"class":6}]